Nutra Pharma Announces Updated Interviews With Wall Street Buy Sell Hold
October 22 2013 - 8:00AM
Marketwired
Nutra Pharma Is Announcing an Updated Interview With Chris
Castaldo and Wall Street Buy Sell Hold
CORAL SPRINGS, FL-(Marketwired - Oct 22, 2013) - Nutra
Pharma Corporation (OTCQB: NPHC), a biotechnology company that is
developing treatments for Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain,
announced today that their Chief Executive Officer, Rik J Deitsch,
was interviewed by Chris Castaldo of Wall Street Buy Sell Hold. The
interview is an update to the previous one posted in August and
provides an outline for the short, mid-term and long-term goals of
the company. Castaldo also updated his interview with Jonathan
Flicker, the CEO of Nutra Pharma's Nyloxin® Distributor, New
Vitality.
"I was excited to have this continuing opportunity to update the
public on the Company," commented Rik J Deitsch, CEO of Nutra
Pharma Corporation. "We have accomplished a lot of great things
since the last interview and still have a lot happening over the
next few months. This interview provided a perfect forum for
letting our shareholders and the public see our present efforts and
future goals," he concluded.
The stated goal at Wall Street Buy Sell Hold (WSBSH) is to
identify cutting edge growth companies that offer unique products
and services. They then alert individual and professional
investors about their discoveries.
"Investing in small and micro-cap stocks can be extremely
volatile," stated Chris Castaldo, CEO of Wall Street Buy Sell Hold.
"However, with the markets indices at or near all time highs,
investors are looking elsewhere to achieve above average gains. I
conducted my first interview with the executives from Nutra Pharma
and New Vitality in mid-August and I wanted to get an update on
their progress since then. I went back to the conference room of
New Vitality (Farmingdale, NY), with both Jonathan Flicker and Rik
Deitsch for this second interview," he continued. "I continue to
believe that we have identified an enormous opportunity and take
great pleasure in sharing our findings with the investing public,"
Castaldo concluded.
In June, Nutra Pharma announced that New Vitality would be
test-marketing Nyloxin®, Nutra Pharma's homeopathic treatment for
chronic pain. At the end of August, the Company announced that they
had delivered the first order of Nyloxin® to New Vitality to begin
distribution. For the past 16 years New Vitality has been marketing
and selling vitamins, health supplements, and personal care
products. Customers learn about their products from advertisements
which use celebrities, sport athletes and doctors to promote them
on over 2000 radio and television stations nationwide. New
Vitality's catalog contains over 150 items which range from energy
supplements to fruit and vegetable supplements to colon cleanses
and products for men's health.
The interview with Rik Deitsch, CEO of Nutra Pharma, can be
viewed at: http://tinyurl.com/nutra-interview2
The interview with Jonathan Flicker, CEO of New Vitality, can be
viewed at: http://tinyurl.com/JF-interview2
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a
biotechnology company specializing in the acquisition, licensing,
and commercialization of pharmaceutical products and technologies
for the management of neurological disorders, cancer, autoimmune,
and infectious diseases, including Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
The Company markets several drug products for sale for the
treatment of pain under the brands Cobroxin® and Nyloxin™. For
additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or http://www.nyloxin.com.
SEC Disclaimer This press release contains forward-looking
statements. The words or phrases "would be," "will allow," "intends
to," "will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The WSBSH interviews should not be
construed as an indication in any way whatsoever of the future
value of the Company's common stock or its present or future
financial condition. The Company's filings may be accessed at the
SEC's Edgar system at www.sec.gov. Statements made herein are
as of the date of this press release and should not be relied upon
as of any subsequent date. The Company cautions readers not to
place reliance on such statements. Unless otherwise required by
applicable law, we do not undertake, and we specifically disclaim
any obligation, to update any forward-looking statements to reflect
occurrences, developments, unanticipated events or circumstances
after the date of such statement.
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Apr 2023 to Apr 2024